Treatment of primary dysmenorrhea in adult women

INTRODUCTION

Primary dysmenorrhea (PD) refers to the presence of recurrent, crampy, lower abdominal pain that occurs during menses in the absence of demonstrable pelvic disease. The management of women with PD will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of PD are discussed separately. (See "Pathogenesis, clinical manifestations, and diagnosis of primary dysmenorrhea in adult women".)

GENERAL APPROACH

Grading dysmenorrhea according to the severity of pain and limitation of daily activities may help guide treatment decisions (table 1). General measures for therapy include patient reassurance and education. In most women with PD, therapy can be initiated empirically.

Nonpharmacological interventions

Heat — Application of heat to the lower abdomen appears to be as effective as oral analgesics for relief of dysmenorrhea.

  • One trial randomly assigned women to receive a heated patch plus placebo tablet, an unheated patch plus ibuprofen (400 mg), a heated patch plus ibuprofen, or an unheated patch and placebo tablet [1]. Women assigned a heated abdominal patch or ibuprofen achieved comparable pain relief and significantly greater pain relief than those assigned an unheated patch and placebo tablet. The combination of a heated abdominal patch plus ibuprofen did not provide greater total pain relief than an unheated abdominal patch plus ibuprofen. However, the combination of a heated abdominal patch plus ibuprofen reduced the time to noticeable pain relief compared to an unheated abdominal patch plus ibuprofen.
  • A second trial by the same group randomly assigned women with dysmenorrhea to an abdominal heat wrap (40 degrees Celsius) which was worn for eight hours, a placebo wrap, acetaminophen (1000 mg every five hours, four times per day for one day), or placebo pills [2]. The heat wrap provided better pain relief than acetaminophen and was well tolerated.

Dietary, vitamin, and herbal treatments — A variety of dietary and vitamin therapies may reduce the severity of menstrual pain, but data are limited to a few small studies. Although the limited available data appear promising, we do not suggest these interventions for our patients at this time.

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Akin, MD, Weingand, KW, Hengehold, DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001; 97:343.
  2. Akin, M, Price, W, Rodriguez, G Jr, et al. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004; 49:739.
  3. Barnard, ND, Scialli, AR, Hurlock, D, Bertron, P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol 2000; 95:245.
  4. Ziaei, S, Faghihzadeh, S, Sohrabvand, F, et al. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea. BJOG 2001; 108:1181.
  5. Ziaei, S, Zakeri, M, Kazemnejad, A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112:466.
  6. Proctor, ML, Murphy, PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001; :CD002124.
  7. Zhu, X, Proctor, M, Bensoussan, A, et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD005288.
  8. Golomb, LM, Solidum, AA, Warren, MP. Primary dysmenorrhea and physical activity. Med Sci Sports Exerc 1998; 30:906.
  9. Metheny, WP, Smith, RP. The relationship among exercise, stress, and primary dysmenorrhea. J Behav Med 1989; 12:569.
  10. Proctor, ML, Murphy, PA, Pattison, HM, et al. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD002248.
  11. Fedele, L, Marchini, M, Acaia, B, et al. Dynamics and significance of placebo response in primary dysmenorrhea. Pain 1989; 36:43.
  12. Owen, PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 1984; 148:96.
  13. Zhang, WY, Li Wan, Po A. Efficacy of minor analgesics in primary dysmenorrhea: a systematic review. Br J Obstet Gynaecol 1998; 105;780.
  14. Budoff, PW. Use of mefanamic acid in the treatment of primary dysmenorrhea. JAMA 1979; 241:2713.
  15. Milsom, I, Minic, M, Dawood, MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther 2002; 24:1384.
  16. Pall, M, Friden, BE, Brannstrom, M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.
  17. Uhler, ML, Hsu, JW, Fisher, SG, Zinaman, MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril 2001; 76:957.
  18. Toppozada, M, El-Abd, M, El-Sokkary, H, El-Rahman, HA. Effect of a prostaglandin inhibitor of human ovulation. Singapore J Obstet Gynecol 1979; 10:42.
  19. Lundstrom, V, Landgren, BM, Eneroth, P, Johannisson, E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstet Gynecol Scand Suppl 1983; 113:77.
  20. Athanasiou, S, Bourne, TH, Khalid, A, et al. Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women. Fertil Steril 1996; 65:556.
  21. Killick, S, Elstein, M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987; 47:773.
  22. Norman, RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358:1287.
  23. Norman, RJ, Wu, R. The potential danger of COX-2 inhibitors. Fertil Steril 2004; 81:493.
  24. Endrikat, J, Jaques, MA, Mayerhofer, M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52:229.
  25. Proctor, ML, Roberts, H, Farquhar, CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea (Cochrane Review). Cochrane Database Syst Rev 2001; 4:CD002120.
  26. Hendrix, SL, Alexander, NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66:393.
  27. Davis, AR, Westhoff, C, O'Connell, K, Gallagher, N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97.
  28. Edelman, AB, Gallo, MF, Jensen, JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.
  29. Anderson, FD, Hait, H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.
  30. Anderson, FD, Gibbons, W, Portman, D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006; 73:229.
  31. Audet, MC, Moreau, M, Koltun, WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347.
  32. Roumen, FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.
  33. Harel, Z, Biro, FM, Kollar, LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health 1995; 16:379.
  34. Varma, R, Sinha, D, Gupta, JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125:9.
  35. Wildemeersch, D, Schacht, E, Wildemeersch, P. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6:192.
  36. Croxatto, HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:21.
  37. Walch, K, Unfried, G, Huber, J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.
  38. Moya, RA, Moisa, CF, Morales, F, et al. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 2000; 69:113.
  39. Facchinetti, F, Sgarbi, L, Piccinini, F, Volpe, A. A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial. Gynecol Endocrinol 2002; 16:39.
  40. Morgan, PJ, Kung, R, Tarshis, J. Nitroglycerin as a uterine relaxant: a systematic review. J Obstet Gynaecol Can 2002; 24:403.
  41. Ulmsten, U. Calcium blockade as a rapid pharmacological test to evaluate primary dysmenorrhea. Gynecol Obstet Invest 1985; 20:78.
  42. Andersson, KE, Ulmsten, U. Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol 1978; 85:142.
  43. Sandahl, B, Ulmsten, U, Andersson, KE. Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea. Arch Gynecol 1979; 227:147.
  44. Helms, JM. Acupuncture for the management of primary dysmenorrhea. Obstet Gynecol 1987; 69:51.
  45. Proctor, ML, Smith, CA, Farquhar, CM, Stones, RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea (Cochrane Review). Cochrane Database Syst Rev 2002; :CD002123.
  46. Witt, CM, Reinhold, T, Brinkhaus, B, et al. Acupuncture in patients with dysmenorrhea: a randomized study on clinical effectiveness and cost-effectiveness in usual care. Am J Obstet Gynecol 2008; 198:166.
  47. Dawood, MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108:428.
  48. Smith, RP, Heltzel, JA. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report. J Reprod Med 1991; 36:260.
  49. Proctor, ML, Latthe, PM, Farquhar, CM, et al. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2005; :CD001896.
  50. Juang, CM, Chou, P, Yen, MS, et al. Laparoscopic uterosacral nerve ablation with and without presacral neurectomy in the treatment of primary dysmenorrhea: a prospective efficacy analysis. J Reprod Med 2007; 52:591.
  51. Chen, FP, Chang, SD, Chu, KK, Soong, YK. Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea. J Reprod Med 1996; 41:463.
  52. Papasakelariou, C. Long-term results of laparoscopic uterosacral nerve ablation. Gynaecological Endoscopy 1996; 5:177.
  53. Proctor, M, Hing, W, Johnson, T, Murphy, P. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2006; 3:CD002119.
  54. Brouard, R, Bossmar, T, Fournie-Lloret, D, et al. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG 2000; 107:614.
  55. Liedman, R, Grant, L, Igidbashian, S, et al. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand 2006; 85:207.
  56. Ling, FW, for the Pelvic Pain Study Group. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Obstet Gynecol 1999; 93:51.
  57. ACOG Practice Bulletin Number 11. Medical Management of Endometriosis. December 1999.
  58. Biberoglu, KO, Behrman, SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 1981; 139:645.
white circle LOG IN
white circle DEMO